China Biologic Products, Inc., through its indirect majority-owned subsidiary, Shandong Taibang, is currently the only plasma-based biopharmaceutical company approved by the government of Shandong Province, the second largest province with a population of 93 million. The company is engaged primarily in research, manufacturing, and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China.
Advanced Description :
No additional details have been entered yet. If you would like to moderate the board and provide an advanced description for this stock, please send a Board Moderation Request at top left of board.